Aprovix is a medical technology company with its registered office in Danderyd, right outside of Stockholm, Sweden. Aprovix was founded in 2001, based on an idea by Professor Erik Wilander of Uppsala.
ALEXANDRA DE WEVER TRESCHOW, CEO
Until recently a senior management consultant and co-owner of a consultancy firm. Eight years of experience in business development and financial and operations analyses in health care. An MBA from the USA and a Ph.D. from Karolinska Institute in gene therapy, related to viruses and cancer. Proven innovator with track record of patents and entrepreneurial success.
SVEN MATTSSON, CHAIRMAN of board
Sven has broad international experience of corporate management from various sectors. He worked for Oriflame Cosmetics between 1988-2005 in leading positions, the last 5 years as the CEO. Sven is a Board member of several companies and is managing his own investment company and working as a consultant to various Private Equity companies. He studied at the Stockholm School of Economics and Harvard Business School (AMP).
ERIK WILANDER, Inventor of qvintip
Erik holds certifications as MD; with specialist certifications in Clinical Cytology and Surgical Pathology. Between 1985 and 2010 Erik was Chairman of the Department of Clinical Cytology at the University Hospital in Uppsala and Professor in clinical pathology from 2001. He has initiated and taken part of 280 publications in scientific journals; mainly in endocrine pathology, clinical cytology, cervical cancer and HPV related diseases. First to use dry self–sampling kits to women for HPV screening.
LEENA NIEMISTÖ, MEmBER OF BOARD OF DIRECTORS
Holds a certification as MD and a PhD. She is a health care professional with 30 yrs of clinical and leadership experience. CEO at healthcare company Dextra (2003-2016) and deputy CEO at healthcare company Pihlajalinna (2013-2016). Professional board member in several publicly listed companies and angel investor in 23 startups.